8-K: Cingulate Inc. Faces Nasdaq Delisting Threat Due to Share Price Non-Compliance

Cingulate Inc. has received a delisting notice from Nasdaq due to its failure to maintain a minimum share price of $1.00, and the company intends to request a hearing to appeal the decision.

Summary

• Cingulate Inc. received a letter from Nasdaq on June 17, 2024, indicating that the company is not in compliance with the $1.00 minimum bid price requirement for continued listing.
• The company's stock price has been below $1.00 for the last 30 consecutive business days, triggering the delisting notice.
• Cingulate is subject to a discretionary panel monitor until May 21, 2025, which prevented Nasdaq from granting additional time to regain compliance.
• The company plans to request a hearing before the Nasdaq Hearings Panel to appeal the delisting and request an extension to regain compliance.
• Cingulate intends to take steps to evidence compliance, including a potential reverse stock split, but there is no guarantee of success.
• The request for a hearing will temporarily halt any delisting action pending the hearing and any extension granted by the Panel.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and the uncertainty surrounding the company's ability to regain compliance. While the company is taking steps to address the issue, the outcome is not guaranteed.

Positives

• Cingulate is taking immediate action by requesting a hearing to appeal the delisting notice.
• The company is exploring a reverse stock split as a potential solution to regain compliance.
• The hearing request will temporarily prevent delisting while the appeal is being considered.

Negatives

• Cingulate's stock price has been below the required $1.00 minimum for 30 consecutive business days.
• The company is subject to a discretionary panel monitor, limiting its options for regaining compliance.
• There is no guarantee that the Nasdaq Hearings Panel will grant an extension or that the company will regain compliance.

Risks

• There is a risk that the Nasdaq Hearings Panel will not grant an extension for Cingulate to regain compliance.
• The company may not be able to successfully implement a reverse stock split or other measures to increase its share price.
• Failure to regain compliance could result in the delisting of Cingulate's securities from Nasdaq.
• Delisting could negatively impact the company's ability to raise capital and its overall valuation.

Future Outlook

Cingulate intends to request a hearing and take definitive steps, including a potential reverse stock split, to regain compliance with Nasdaq listing requirements, but there is no assurance of success.

Management Comments

• The company fully intends to timely request a hearing before the Panel.
• The company intends to continue to take definitive steps in an effort to evidence compliance with the Bid Price Requirement, including by effecting a reverse stock split.

Industry Context

This delisting notice highlights the challenges faced by companies with low stock prices in maintaining their listing on major exchanges like Nasdaq. It is not uncommon for companies to face delisting threats due to non-compliance with minimum bid price requirements.

Comparison to Industry Standards

• Many companies in the biotech and pharmaceutical sectors, especially those in early stages of development, face challenges in maintaining a minimum share price.
• A reverse stock split is a common strategy used by companies to increase their share price and regain compliance with listing requirements.
• Other companies that have faced similar delisting notices include [hypothetical company A] and [hypothetical company B], which also had to implement reverse stock splits or other measures to regain compliance.
• The success rate of companies regaining compliance after receiving a delisting notice varies, and it often depends on the company's financial health and future prospects.

Stakeholder Impact

• Shareholders face the risk of delisting, which could negatively impact the value of their investment.
• Employees may experience uncertainty about the company's future.
• Customers and suppliers may be concerned about the company's long-term viability.

Next Steps

• Cingulate will request a hearing before the Nasdaq Hearings Panel.
• The company will seek an extension to regain compliance with the minimum bid price requirement.
• Cingulate will consider a reverse stock split to increase its share price.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, reverse stock split, hearing, Cingulate, stock price